Memantine 5 mg, 10 mg, 10 mg/5 ml Suppliers & Bulk Manufacturers

Available Forms: Tablets / Oral solution

Available Strengths: 5 mg, 10 mg, 10 mg/5 ml

Reference Brands: Namenda (USA), Ebixa (EU/UK)

Category: Neurology

Memantine is an NMDA receptor antagonist used in the management of moderate to severe Alzheimer’s disease. It works by regulating glutamate activity in the brain, which can help improve memory, attention, and overall cognitive function.

Product Description:

Memantine is an uncompetitive, low-affinity NMDA receptor antagonist. Its value lies in the kinetics: it enters the NMDA channel only when the channel is open and leaves quickly, so it dampens the sustained low-level glutamate stimulation thought to contribute to neuronal damage in Alzheimer's disease while largely preserving the brief, high-concentration glutamate signalling that learning and memory depend on. Stronger NMDA blockers such as ketamine lack that selectivity.

It is licensed for moderate to severe Alzheimer's disease, alone or with a cholinesterase inhibitor, and gives a modest symptomatic benefit on cognition, daily function and behaviour. It is titrated weekly in 5 mg steps to 20 mg daily. It is well tolerated — dizziness, headache, constipation and occasional agitation or confusion are the main adverse effects. Elimination is largely renal and unchanged, so the dose is reduced in severe renal impairment, and urinary alkalinisation reduces clearance.

Sourcing notes. Generic, widely registered and low-cost. Tablets carry most of the volume, and the oral solution serves patients with swallowing difficulty. Titration packs containing mixed strengths are a separate presentation that some markets register independently. Fixed-dose extended-release combinations with donepezil exist in the US but are a distinct product.